Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC clarifies vaccine guidelines and mixing

The Centers for Disease Control and Prevention updated its guidance on Thursday on the administration of the two coronavirus vaccines currently approved for Emergency Use Authorization.

The guidance clarifies several questions public health practitioners have recently asked. Can the two doses of the Pfizer and Moderna vaccines be split, and how long do patients have to get the second dose of the vaccine?

Both doses of the vaccine require patients to return for a booster. For the Pfizer vaccine, the second dose is recommended three weeks after the first dose. The second dose of the Moderna vaccine is due four weeks later.

The CDC said that it continues to recommend that the same type of vaccine be administered to patients. But if only the opposite type of vaccine is available, the CDC said that the other vaccine can be administered and is considered effective.

Source: CDC

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!